Evidio Domingo-Musibay

Assistant Professor of Medicine

University of Minnesota Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Evidio Domingo-Musibay is an Assistant Professor of Medicine at the University of Minnesota Medical Center in the United States. His research primarily focuses on melanoma and includes recent studies on neoadjuvant therapies, tumor-infiltrating lymphocyte cell therapy, and the impact of the microbiome. He has contributed significantly to clinical trials such as the NeoACTIVATE trial and the SALVO study, demonstrating a commitment to advancing treatment options for high-risk melanoma patients.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Jane Yuet Ching Hui

University of Minnesota

UNITED STATES

View details

Alessio Giubellino, MD PhD

Associate Professor

UNITED STATES

View details

Mohammed Milhem

Oncology Section Chief

University of Iowa Healthcare

UNITED STATES

View details

Anthony Olszanski

Vice Chair Research; Associate Professor

UNITED STATES

View details

Yousef Zakharia

The University of Iowa

UNITED STATES

View details

Tina Hieken

Professor of Surgery

Mayo Clinic Minnesota

UNITED STATES

View details

Heather Nelson

University of Minnesota

UNITED STATES

View details

Keith Skubitz

Professor

University of Minnesota

UNITED STATES

View details

Giao Phan

University of Connecticut Health Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Evidio Domingo-Musibay

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review.

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.

Sentinel lymph node tumour burden using digital cell count estimation predicts outcomes in melanoma

A functional variant in the immune signalling receptor NKG2D alters skin cancer risk

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide

Oncologic outcomes of patients with lymph node-positive Merkel cell carcinoma with unknown primary: A retrospective cohort study.

Sentinel lymph node tumour burden using digital cell count estimation predicts outcomes in melanoma

Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide.

Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience

Collaborators (9)

Jane Yuet Ching Hui

Alessio Giubellino, MD PhD

Mohammed Milhem

Anthony Olszanski

Yousef Zakharia

Tina Hieken

Heather Nelson

Keith Skubitz

Giao Phan

Make your next move.